Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas.
Premnath N, Liu Y, Reves H, Pandey U, Nair RG, Anderson J, Afrough A, Anderson LD Jr, Chung SS, Kaur G, Khan AM, Kumar KA, Madanat YF, Wolfe HR, Yilmaz E, Awan FT, Sweetenham J, Ramakrishnan Geethakumari P. Premnath N, et al. Among authors: anderson ld jr. JCO Oncol Pract. 2024 Oct 17:OP2400354. doi: 10.1200/OP.24.00354. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39418621
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
Badros AZ, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin T, Voorhees PM. Badros AZ, et al. Among authors: anderson ld jr. Blood. 2024 Sep 27:blood.2024025746. doi: 10.1182/blood.2024025746. Online ahead of print. Blood. 2024. PMID: 39331724
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Chari A, et al. Among authors: anderson ld jr. Blood Cancer J. 2024 Jul 8;14(1):107. doi: 10.1038/s41408-024-01088-6. Blood Cancer J. 2024. PMID: 38977707 Free PMC article. Clinical Trial.
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
Dima D, Goel U, Sannareddy A, Ibeh N, Ullah F, Afrough A, Mazzoni S, Mehdi A, Rudoni J, Raza S, De Simone N, Williams L, Khan A, Rashid A, Rice M, Ricci K, Samaras C, Valent J, Anderson LD Jr, Anwer F, Kaur G, Khouri J. Dima D, et al. Among authors: anderson ld jr. Hematol Oncol. 2024 Jul;42(4):e3293. doi: 10.1002/hon.3293. Hematol Oncol. 2024. PMID: 38872511
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Zanwar S, et al. Among authors: anderson ld jr. J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4. J Hematol Oncol. 2024. PMID: 38845015 Free PMC article.
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD Jr, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Khouri J, et al. Among authors: anderson ld jr. Transplant Cell Ther. 2024 Aug;30(8):790.e1-790.e16. doi: 10.1016/j.jtct.2024.05.025. Epub 2024 Jun 2. Transplant Cell Ther. 2024. PMID: 38834151 Free article.
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group. Lin Y, et al. Among authors: anderson ld jr. Lancet Oncol. 2024 Aug;25(8):e374-e387. doi: 10.1016/S1470-2045(24)00094-9. Epub 2024 May 28. Lancet Oncol. 2024. PMID: 38821074 Review.
Toxicity of CAR T-Cell Therapy for Multiple Myeloma.
Afrough A, Abraham PR, Turer L, Kaur G, Sannareddy A, Hansen DK, Anderson LD Jr. Afrough A, et al. Among authors: anderson ld jr. Acta Haematol. 2024 May 8:1-15. doi: 10.1159/000539134. Online ahead of print. Acta Haematol. 2024. PMID: 38718775 Free article. Review.
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. Callander NS, et al. Among authors: anderson ld jr. Blood Cancer J. 2024 Apr 22;14(1):69. doi: 10.1038/s41408-024-01030-w. Blood Cancer J. 2024. PMID: 38649340 Free PMC article. Clinical Trial.
78 results